Absence of effects of ketanserin on renal prostacyclin and thromboxane A2 in essential hypertension

The anti-hypertensive effect of ketanserin, a new antagonist of 5-HT2-serotonergic receptors, was evaluated in 10 patients with uncomplicated essential hypertension. At the end of 2 weeks of placebo wash-out and following 2 and 4 weeks of treatment with ketanserin (20 mg twice daily), blood pressure...

Full description

Saved in:
Bibliographic Details
Published in:European heart journal 1991-04, Vol.12 (4), p.550-553
Main Authors: GAMBINI, G., ROSSI, S., VALORI, C.
Format: Article
Language:English
Subjects:
6-Ketoprostaglandin F1 alpha - urine
Adult
Aged
Epoprostenol - biosynthesis
Essential hypertension
Female
Humans
Hypertension - drug therapy
Hypertension - metabolism
Hypertension - physiopathology
ketanserin
Ketanserin - pharmacology
Kidney - drug effects
Kidney - metabolism
Male
Middle Aged
renal prostacyclin
renal thromboxane
Renin-Angiotensin System - drug effects
renin-angiotensin-aldosterone system
Thromboxane A2 - biosynthesis
Thromboxane B2 - urine
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The anti-hypertensive effect of ketanserin, a new antagonist of 5-HT2-serotonergic receptors, was evaluated in 10 patients with uncomplicated essential hypertension. At the end of 2 weeks of placebo wash-out and following 2 and 4 weeks of treatment with ketanserin (20 mg twice daily), blood pressure and heart rate were measured both in the supine and standing position. In addition, before and at the end of treatment, plasma renin activity ( PRA), plasma concentration of aldosterone and the nocturnal urinary excretion of 6-keto-PGFla and TXB2, the two metabolites that largely reflect the renal synthesis of prostacyclin and thromboxane, respectively, were determined. The study was carried out in a metabolic ward where the intake of sodium was adjusted to 100–120 mmol day−1. Ketanserin significantly reduced blood pressure both in the supine and standing position with no significant change of heart rate. The treatment did not produce any variation of PRA, aldosterone, urinary excretion of6-keto-PGFla or TXB2. These results indicate that ketanserin reduces blood pressure without interfering with the renin-angiotensin-aldosterone system or the renal synthesis of prostacyclin and thromboxane.
ISSN:0195-668X
1522-9645
DOI:10.1093/oxfordjournals.eurheartj.a059937